| Market Capitalization (Millions $) |
4 |
| Shares
Outstanding (Millions) |
1 |
| Employees |
39 |
| Revenues (TTM) (Millions $) |
3 |
| Net Income (TTM) (Millions $) |
-11 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Collplant Biotechnologies Ltd is an Israeli biotechnology company that specializes in the development and commercialization of collagen-based medical products. The company uses plant-based genetic engineering to produce recombinant human collagen, which is used in various applications such as tissue repair, wound healing, and aesthetic medicine.
Collplant's flagship product, called VergenixSTR, is a bioengineered collagen matrix that promotes the healing and regeneration of damaged tissues. The company also develops collagen-based cosmetic products for the treatment of wrinkles and skin rejuvenation.
Collplant collaborates with academic institutions and commercial partners to further advance its technology and expand its product pipeline. The company is known for its innovative research and development efforts in the field of regenerative medicine.
Overall, Collplant Biotechnologies Ltd is focused on harnessing the potential of collagen-based biotechnology to provide innovative medical solutions for a range of applications.
Company Address: 4 Oppenheimer Rehovot 7670104
Company Phone Number: 73 232 5600 Stock Exchange / Ticker: NASDAQ CLGN
|
